The P Word Right to the Pivot

In the earliest days of the company, you weren't developing ASOs to go after regulatory RNA. At the risk of getting too detailed in the science, you were developing small molecules to hit signaling pathways that could indirectly impact how genes are regulated. That experiment ultimately didn't bear out, or at least Didn't bear out as you would have hoped. And you made a very difficult decision and executed a very, I would say challenging pivot in the company to refocus the platform on a different type of medicine going after a differenttype of target.